Company Description

Virogenbio is a clinical stage biotechnology company with expertise in both US and Asia.  Unlike earlier generation immunotoxins, VG712 induces a rapid and transient T cell depletion without triggering cytokine response.  By targeting CD3 receptors, VG712 is effective against all T cell subtypes.  Virogen owns the global rights to develop and commercialize this novel fusion protein and has completed the CMC development of drug products for global clinical trials.